Filtered By:
Vaccination: Cancer Vaccines
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 8118 results found since Jan 2013.
Outer membrane vesicle-based intranasal vaccines
Curr Opin Immunol. 2023 Aug 18;84:102376. doi: 10.1016/j.coi.2023.102376. Online ahead of print.ABSTRACTDelivery of vaccines via the mucosal route is regarded as the most effective mode of immunization to counteract infectious diseases that enter via mucosal tissues, including oral, nasal, pulmonary, intestinal, and urogenital surfaces. Mucosal vaccines not only induce local immune effector elements, such as secretory Immunoglobulin A (IgA) reaching the luminal site of the mucosa, but also systemic immunity. Moreover, mucosal vaccines may trigger immunity in distant mucosal tissues because of the homing of primed antigen-s...
Source: Current Opinion in Immunology - August 20, 2023 Category: Allergy & Immunology Authors: Peter Van der Ley Virgil Ejc Schijns Source Type: research
Perspectives on Advancing Countermeasures for Filovirus Disease: Report from a Multi-Sector Meeting
Discussion participants recommended a follow-up meeting be held in Africa with national public health and research agencies from at-risk countries to establish such a consortium.PMID:37596837 | DOI:10.1093/infdis/jiad354
Source: Cancer Control - August 19, 2023 Category: Cancer & Oncology Authors: Armand Sprecher Robert Cross Andrea Marzi Karen A Martins Daniel Wolfe Joel M Montgomery Christina F Spiropoulou Tomas Cihlar Steve Ahuka-Mundeke Tara Nyhuis Carrie Teicher Ian Crozier Jim Strong Gary Kobinger Courtney Woolsey Thomas W Geisbert Heinz Feld Source Type: research
Use of cancer vaccine after immunotherapy failure: a promising strategy for advanced NSCLC patients with secondary resistance to checkpoint inhibitors
Ann Oncol. 2023 Aug 17:S0923-7534(23)00799-8. doi: 10.1016/j.annonc.2023.08.002. Online ahead of print.NO ABSTRACTPMID:37597581 | DOI:10.1016/j.annonc.2023.08.002
Source: Ann Oncol - August 19, 2023 Category: Cancer & Oncology Authors: O Adotevi Source Type: research
Reduced SARS-CoV-2 mRNA vaccine immunogenicity and protection in mice with diet-induced obesity and insulin resistance
CONCLUSION: We demonstrate impaired immunity following SARS-CoV-2 mRNA immunization in a murine model of comorbid T2DM and obesity, supporting the need for further research into the basis for impaired anti-SARS-CoV-2 immunity in T2DM and investigation of novel approaches to enhance vaccine immunogenicity among those with metabolic diseases.PMID:37595760 | DOI:10.1016/j.jaci.2023.06.031
Source: Clinical Lung Cancer - August 18, 2023 Category: Cancer & Oncology Authors: Timothy R O'Meara Etsuro Nanishi Marisa E McGrath Soumik Barman Danica Dong Carly Dillen Manisha Menon Hyuk-Soo Seo Sirano Dhe-Paganon Robert K Ernst Ofer Levy Matthew B Frieman David J Dowling Source Type: research
United States' regulatory approved pharmacotherapies for nuclear reactor explosions and anthrax-associated bioterrorism
Expert Opin Drug Saf. 2023 Aug 18:1-6. doi: 10.1080/14740338.2023.2245748. Online ahead of print.ABSTRACTINTRODUCTION: Nuclear reactor incidents and bioterrorism outbreaks are concerning public health disasters. Little is known about US Food and Drug Administration (FDA)-approved agents that can mitigate consequences of these events. We review FDA data supporting regulatory approvals of these agents.AREAS COVERED: We reviewed pharmaceutical products approved to treat Hematopoietic Acute Radiation Syndrome (H-ARS) and to treat or prevent pulmonary infections following Bacillus anthracis (anthrax) exposure. Four drugs were a...
Source: Expert Opinion on Drug Safety - August 18, 2023 Category: Drugs & Pharmacology Authors: Charles L Bennett Peter Georgantopoulos Robert Peter Gale Kevin Knopf William J Hrushesky Chadi Nabhan James O Armitage Source Type: research
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency
Nat Commun. 2023 Aug 18;14(1):5032. doi: 10.1038/s41467-023-40758-0.ABSTRACTT-cell immunity is central for control of COVID-19, particularly in patients incapable of mounting antibody responses. CoVac-1 is a peptide-based T-cell activator composed of SARS-CoV-2 epitopes with documented favorable safety profile and efficacy in terms of SARS-CoV-2-specific T-cell response. We here report a Phase I/II open-label trial (NCT04954469) in 54 patients with congenital or acquired B-cell deficiency receiving one subcutaneous CoVac-1 dose. Immunogenicity in terms of CoVac-1-induced T-cell responses and safety are the primary and seco...
Source: Cancer Control - August 18, 2023 Category: Cancer & Oncology Authors: Jonas S Heitmann Claudia Tandler Maddalena Marconato Annika Nelde Timorshah Habibzada Susanne M Rittig Christian M Tegeler Yacine Maringer Simon U Jaeger Monika Denk Marion Richter Melek T Oezbek Karl-Heinz Wiesm üller Jens Bauer Jonas Rieth Marcel Wacke Source Type: research
Reduced SARS-CoV-2 mRNA vaccine immunogenicity and protection in mice with diet-induced obesity and insulin resistance
CONCLUSION: We demonstrate impaired immunity following SARS-CoV-2 mRNA immunization in a murine model of comorbid T2DM and obesity, supporting the need for further research into the basis for impaired anti-SARS-CoV-2 immunity in T2DM and investigation of novel approaches to enhance vaccine immunogenicity among those with metabolic diseases.PMID:37595760 | DOI:10.1016/j.jaci.2023.06.031
Source: Clinical Lung Cancer - August 18, 2023 Category: Cancer & Oncology Authors: Timothy R O'Meara Etsuro Nanishi Marisa E McGrath Soumik Barman Danica Dong Carly Dillen Manisha Menon Hyuk-Soo Seo Sirano Dhe-Paganon Robert K Ernst Ofer Levy Matthew B Frieman David J Dowling Source Type: research
United States' regulatory approved pharmacotherapies for nuclear reactor explosions and anthrax-associated bioterrorism
Expert Opin Drug Saf. 2023 Aug 18:1-6. doi: 10.1080/14740338.2023.2245748. Online ahead of print.ABSTRACTINTRODUCTION: Nuclear reactor incidents and bioterrorism outbreaks are concerning public health disasters. Little is known about US Food and Drug Administration (FDA)-approved agents that can mitigate consequences of these events. We review FDA data supporting regulatory approvals of these agents.AREAS COVERED: We reviewed pharmaceutical products approved to treat Hematopoietic Acute Radiation Syndrome (H-ARS) and to treat or prevent pulmonary infections following Bacillus anthracis (anthrax) exposure. Four drugs were a...
Source: Expert Opinion on Drug Safety - August 18, 2023 Category: Drugs & Pharmacology Authors: Charles L Bennett Peter Georgantopoulos Robert Peter Gale Kevin Knopf William J Hrushesky Chadi Nabhan James O Armitage Source Type: research
Parental intention to vaccinate daughters with the human papillomavirus vaccine in Korea: a nationwide cross-sectional survey
CONCLUSION: The intention among parents to vaccinate daughters remains relatively low, although it is rising. To increase the HPV vaccination rate, strong recommendations and education should be provided to parents and the younger generation.PMID:37591785 | DOI:10.4178/epih.e2023076
Source: Cancer Control - August 17, 2023 Category: Cancer & Oncology Authors: Yejin Ha Kyeongmin Lee Bomi Park Mina Suh Jae Kwan Jun Kui Son Choi Source Type: research
Italian oncologists and vaccinations against infectious diseases: Results of a survey of the Italian Association of Medical Oncology
CONCLUSION: This is the first survey conducted among Italian oncologists to better understand the perception and attitudes towards the vaccination. It highlights the urgent issues of educating and training oncologists in vaccine-preventable diseases and vaccine awareness and the need to build (or implement) a network of multidisciplinary collaborations.PMID:37586016 | DOI:10.1177/03008916231191547
Source: Herpes - August 16, 2023 Category: Infectious Diseases Authors: Angioletta Lasagna Antonella Brunello Nicola Silvestris Paolo Pedrazzoli Massimo Di Maio Saverio Cinieri Source Type: research
Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects
Nature Reviews Clinical Oncology, Published online: 16 August 2023; doi:10.1038/s41571-023-00811-9In oncology, mRNA–lipid nanoparticles (LNPs) have been used either to achieve intratumoural expression of immune-stimulating cytokine combinations or as cancer vaccines, and new strategies are in development to enable the selective delivery of payloads into cancer cells previously considered unreachable. The authors of this Review present various approaches for delivering mRNA–LNPs to tumours and discuss improvements that will improve the selective targeting of cancer cells with mRNA–LNPs.
Source: Nature Reviews Clinical Oncology - August 16, 2023 Category: Cancer & Oncology Authors: Edo Kon Nitay Ad-El Inbal Hazan-Halevy Lior Stotsky-Oterin Dan Peer Source Type: research
